Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Niagen Bioscience (NAGE) Operating Leases: 2019-2024

Historic Operating Leases for Niagen Bioscience (NAGE) over the last 6 years, with Dec 2024 value amounting to $2.6 million.

  • Niagen Bioscience's Operating Leases rose 6.90% to $3.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.1 million, marking a year-over-year increase of 6.90%. This contributed to the annual value of $2.6 million for FY2024, which is 21.21% down from last year.
  • As of FY2024, Niagen Bioscience's Operating Leases stood at $2.6 million, which was down 21.21% from $3.3 million recorded in FY2023.
  • Over the past 5 years, Niagen Bioscience's Operating Leases peaked at $4.7 million during FY2021, and registered a low of $1.6 million during FY2020.
  • For the 3-year period, Niagen Bioscience's Operating Leases averaged around $3.4 million, with its median value being $3.3 million (2023).
  • As far as peak fluctuations go, Niagen Bioscience's Operating Leases spiked by 193.75% in 2021, and later declined by 21.43% in 2023.
  • Yearly analysis of 5 years shows Niagen Bioscience's Operating Leases stood at $1.6 million in 2020, then surged by 193.75% to $4.7 million in 2021, then declined by 10.64% to $4.2 million in 2022, then dropped by 21.43% to $3.3 million in 2023, then dropped by 21.21% to $2.6 million in 2024.